While artificial intelligence (AI) has revolutionized healthcare by minimizing the element of human error, thus improving efficiency, limitations do still exist. In this video, Bruce Burnett, MMedSci, of the University of Central Lancashire, Preston, UK, discusses the limitations of utilizing AI programs for prescription screening. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Limitations with AI programs for prescription screening
